Risk factors for disease progression in advanced jejunoileal neuroendocrine tumors

Neuroendocrinology

Volumn 96, Issue 1, 2012, Pages 32-40

  Panzuto, Francesco ^a   Campana, Davide ^b   Fazio, Nicola ^c   Brizzi, Maria Pia ^d   Boninsegna, Letizia ^e,g   Nori, Francesca ^b   Di Meglio, Giovanni ^c   Capurso, Gabriele ^a   Scarpa, Aldo ^f   Dogliotti, Luigi ^d   De Braud, Filippo ^c   Tomassetti, Paola ^b   Delle Fave, Gianfranco ^a   Falconi, Massimo ^e  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b UNIVERSITY OF BOLOGNA   (Italy)

^c EUROPEAN INSTITUTE OF ONCOLOGY   (Italy)

^d UNIVERSITY OF TURIN   (Italy)

^e Surgery B   (Italy)

^f UNIVERSITY OF VERONA   (Italy)

^g SACRO CUORE DON CALABRIA HOSPITAL   (Italy)

Author keywords

Carcinoid; Midgut; Neuroendocrine tumors; Progression free survival; Risk factors

Indexed keywords

ALPHA INTERFERON; ANTINEOPLASTIC AGENT; EVEROLIMUS; KI 67 ANTIGEN; SOMATOSTATIN DERIVATIVE; SUNITINIB;

ADULT; ADVANCED CANCER; ARTICLE; CANCER CHEMOTHERAPY; CANCER STAGING; CHEMOEMBOLIZATION; DISEASE COURSE; DISTANT METASTASIS; FEMALE; FOLLOW UP; HUMAN; JEJUNOILEAL NEUROENDOCRINE TUMOR; KAPLAN MEIER METHOD; LIVER METASTASIS; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY (TOPIC); NEUROENDOCRINE TUMOR; OVERALL SURVIVAL; PEPTIDE RECEPTOR RADIONUCLIDE THERAPY; PREDICTIVE VALUE; PRIORITY JOURNAL; PROGNOSIS; PROGRESSION FREE SURVIVAL; PROPORTIONAL HAZARDS MODEL; RADIOISOTOPE THERAPY; RETROSPECTIVE STUDY; RISK FACTOR; TREATMENT PLANNING; TUMOR GROWTH;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; FEMALE; FOLLOW-UP STUDIES; HUMANS; ILEAL NEOPLASMS; JEJUNAL NEOPLASMS; KAPLAN-MEIER ESTIMATE; KI-67 ANTIGEN; MALE; MIDDLE AGED; NEOPLASM STAGING; NEUROENDOCRINE TUMORS; RETROSPECTIVE STUDIES; RISK FACTORS; TREATMENT OUTCOME;

EID: 84864877732     PISSN: 00283835     EISSN: 14230194     Source Type: Journal    
DOI: 10.1159/000334038     Document Type: Article

References (32)

1. Yao JC, Hassan M, Phan A, Dagohoy C, Leary C, Mares JE, Abdalla EK, Fleming JB, Vauthey JN, Rashid A, Evans DB: One hundred years after carcinoids: epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. J Clin Oncol 2008; 26: 3063-3072.
2. Niederle MB, Hackl M, Kaserer K, Niederle B: Gastroenteropancreatic neuroendocrine tumours: the current incidence and staging based on the WHO and European Neuroen-docrine Tumour Society classification: an analysis based on prospectively collected parameters. Endocr Relat Cancer 2010; 17: 909-918.
3. Ellis L, Shale MJ, Coleman MP: Carcinoid tumors of the gastrointestinal tract: trends in incidence in England since 1972. Am J Gas-troenterol 2010; 105:2563-2569.
4. Modlin IM, Oberg K, Chung DC, Jensen RT, de Herder WW, Thakker RV, Caplin M, Del-le Fave G, Kaltsas GA, Krenning EP, Moss SF, Nilsson O, Rindi G, Salazar R, Ruszniewski P, Sundin A: Gastroenteropancreatic neuro-endocrine tumors. La ncet Oncol 2008; 9: 61-72.
5. Panzuto F, Nasoni S, Falconi M, Corleto VD, Capurso G, Cassetta S, Di Fonzo M, Torna-tore V, Milione M, Angeletti S, Cattaruzza MS, Ziparo V, Bordi C, Pederzoli P, Delle Fave G: Prognostic factors and survival in endocrine tumor patients: comparison between gastrointestinal and pancreatic localization. Endocr Relat Cancer 2005; 12:1083-1092.
6. Tomassetti P, Campana D, Piscitelli L, Casa-dei R, Nori F, Brocchi E, Santini D, Pezzilli R, Corinaldesi R: Endocrine tumors of the ileum: factors correlated with survival. Neu-roendocrinology 2006; 83:380-386.
7. Durante C, Boukheris H, Dromain C, Duvillard P, Leboulleux S, E lias D, de Baere T, Malka D, Lumbroso J, Guigay J, Schlumberger M, Ducreux M, Baudin E: Prognostic factors influencing survival from metastatic (stage IV) gastroenteropancreatic well-differentiated endocrine carcinoma. Endocr Relat Cancer 2009; 16: 585-597.
8. Garcia-Carbonero R, Capdevila J, Crespo-Herrero G, Díaz- Pérez JA, Martínez Del Prado MP, Alonso Orduña V, Sevilla-García I, Villabona-Artero C, Beguiristain-Gómez A, Llanos-Muñoz M, Marazuela M, Alvarez-Escola C, Castellano D, Vilar E, Jiménez-Fonseca P, Teulé A, Sastre-Valera J, Bena-vent- Viñuelas M, Monleon A, Salazar R: Incidence, patterns of care and prognostic factors for outcome of gastroenteropancre-atic neuroendocrine tumors (GEP-NETs): results from the National Cancer Registry of Spain (RGETNE). Ann Oncol 2010; 21:1794-1803.
9. Yao JC, Shah MH, Ito T, Bohas CL, Wolin EM, Van Cutsem E, Hobday TJ, Okusaka T, Capdevila J, de Vries EG, Tomassetti P, Pavel ME, Hoosen S, Haas T, Lincy J, Lebwohl D, Öberg K; RAD001 in Advanced Neuroendo-crine Tumors, Third Trial (RADIANT-3) Study Group: Everolimus for advanced pancreatic neuroendocrine tumors. N Engl J Med 2011; 364: 514-523.
10. Raymond E, Dahan L, Raoul JL, Bang YJ, Borbath I, Lombard-Bohas C, Valle J, Metra-kos P, Smith D, Vinik A, Chen JS, Hörsch D, Hammel P, Wiedenmann B, Van Cutsem E, Patyna S, Lu DR, Blanckmeister C, Chao R, Ruszniewski P: Sunitinib malate for the treatment of pancreatic neuroendocrine tumors. N Engl J Med 2011; 364:501-513.
11. Kaltsas GA, Besser GM, Grossman AG: The diagnosis and management of advanced neuroendocrine tumors. Endocrine Rev 2004; 25:458-511.
12. Rinke A, Müller HH, Schade-Brittinger C, Klose KJ, Barth P, Wied M, Mayer C, Aminossadati B, Pape UF, Bläker M, Harder J, Arnold C, Gress T, Arnold R; PROMID Study Group: Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neu-roendocrine midgut tumors: a report from the PROMID Study Group. J Clin Oncol 2009; 27:4656-4663.
13. Kulke MH, Siu LL, Tepper JE, Fisher G, Jaffe D, Haller DG, Ellis LM, Benedetti JK, Bergs-land EK, Hobday TJ, Van Cutsem E, Ping-pank J, Oberg K, Cohen SJ, Posner MC, Yao JC: Future directions in the treatment of neuroendocrine tumors: consensus report of the National Cancer Institute Neuroendo-crine Tumor clinical trials planning meeting. J Clin Oncol 2011; 29: 934-943.
14. Panzuto F, Boninsegna L, Fazio N, Campana D, Brizzi M P, Capurso G, Scarpa A, De Braud F, Dogliotti L, Tomassetti P, Delle Fave G, Falconi M: Metastatic and locally advanced pancreatic endocrine carcinomas: analysis of factors associated with disease progression. J Clin Oncol 2011; 29: 2372-2377.
15. Pape UF, Berndt U, Muller-Nordhorn J, Bohmig M, Roll S, Koch M, Willich SN, Wie-denmann B: Prognostic factors of long-term outcome in gastroenteropancreatic neuroen-docrine tumours. Endocr Related Cancer 2008; 15:1083-1097.
16. DeLellis RA, Lloyd RV, Heitz PU, Eng C: World Health Organization Classification of Tumours, Pathology and Genetics of Tumours of Endocrine Organs. Lyon, IARC Press, 2004.
17. Rindi G, Klöppel G, Couvelard A, Kommi-noth P, Körner M, Lopes JM, McNicol AM, Nilsson O, Perren A, Scarpa A, Scoazec JY, Wiedenmann B: TNM staging of midgut and hindgut (neuro) endocrine tumors: a consensus proposal including a grading system. Virchows Arch 2007; 451: 757-762.
18. Pelosi G, Bresaola E, Bogina G, Pasini F, Ro-della S, Castelli P, Iacono C, Serio G, Zam-boni G: Endocrine tumors of the pancreas: Ki-67 immunoreactivity on paraffin sections is an independent predictor for malignancy: a comparative study with proliferat-ing-cell nuclear antigen and progesterone receptor protein immunostaining, mitotic index, and other clinicopathologic variables. Hum Pathol 1996; 27:1124-1134.
19. Ekeblad S, Skogseid B, Dunder K, Oberg K, Eriksson B: Prognostic factors and survival in 324 patients with pancreatic endocrine tumor treated at a single institution. Clin Cancer Res 2008; 14:7798-7803.
20. Bettini R, Boninsegna L, Mantovani W, Ca-pelli P, Bassi C, Pederzoli P, Delle Fave GF, Panzuto F, Scarpa A, Falconi M: Prognostic factors at diagnosis and value of WHO classification in a mono-institutional series of 180 non-functioning pancreatic endocrine tumours. Ann Oncol 2008; 19: 903-908.
21. La Rosa S, Klersy C, Uccella S, Dainese L, Albarello L, Sonzogni A, Doglioni C, Capella C, Solcia E: Improved h istologic and clinico-pathologic criteria for prognostic evaluation of pancreatic endocrine tumors. Hum Pathol 2009; 40: 30-40.
22. Scarpa A, Mantovani W, Capelli P, Beghelli S, Boninsegna L, Bettini R, Panzuto F, Ped-erzoli P, Delle Fave G, Falconi M: Pancreatic endocrine tumors: improved TNM staging and histopathological grading permit a clinically efficient prognostic stratification of patients. Mod Pathol 2010; 23: 824-833.
23. Ahmed A, Turner G, King B, Jones L, Culli-ford D, McCance D, Ardill J, Johnston BT, Poston G, Rees M, Buxton-Thomas M, Cap-lin M, Ramage JK: Midgut neuroendocrine tumours with liver metastases: results of the UKINETS study. Endocr Relat Cancer 2009; 16:885-894.
24. Bergestuen DS, Aabakken L, Holm K, Vatn M, Thiis-Evensen E: Small intestinal neuro-endocrine tumors: prognostic factors and sur vival. Scand J Gastroenterol 2009; 44: 1084-1091.
25. Rindi G, Klöppel G, Alhman H, Caplin M, Couvelard A, de Herder WW, Erikssson B, Falchetti A, Falconi M, Komminoth P, Körn-er M, Lopes JM, McNicol AM, Nilsson O, Perren A, Scarpa A, Scoazec JY, Wieden-mann B; and all other Frascati Consensus Conference participants; European Neuro-endocrine Tumor Society (ENETS): TNM staging of foregut (neuro)endocrine tumors: a consensus proposal including a grading system. Virchows Arch 2006; 449: 395-401.
26. Jann H, Roll S, Couvelard A, Hentic O, Pavel M, Müller-Nordhorn J, Koch M, Röcken C, Rindi G, Ruszniewski P, Wiedenmann B, Pape UF: Neuroendocrine tumors of midgut and hindgut origin: tumor-node-metastasis classification determines clinical outcome. Cancer 2011; 117:3332-3341.
27. Faiss S, Pape UF, Böhmig M, Dörffel Y, Mansmann U, Golder W, Riecken EO, Wie-denmann B; International Lanreotide and Interferon Alfa Study Group: Prospective, randomized, multicenter trial on the anti-proliferative effect of lanreotide, interferon alfa, and their combination for therapy of metastatic neuroendocrine gastroentero-pancreatic tumors-the International Lan-reotide and Interferon Alfa Study Group. J Clin Oncol 2003; 21:2689-2696.
28. Arnold R, Rinke A, Klose KJ, Müller HH, Wied M, Zamzow K, Schmidt C, Schade-Brittinger C, Barth P, Moll R, Koller M, Un-terhalt M, Hiddemann W, Schmidt-Lauber M, Pavel M, Arnold CN: Octreotide versus octreotide plus interferon-alpha in endocrine gastroenteropancreatic tumors: a randomized trial. Clin Gastroenterol Hepatol 2005; 3:761-771.
29. Mazumdar M, Smith A, Schwartz LH: A statistical simulation study finds discordance between WHO criteria and RECIST guideline. J Clin Epidemiol 2004; 57: 358-365.
30. Eriksson B, Klöppel G, Krenning E, Ahlman H, Plöckinger U, Wiedenmann B, Arnold R, Auernhammer C, Körner M, Rindi G, Wildi S; Frascati Consensus Conference participants: Consensus guidelines for the management of patients with digestive neuroendo-crine tumors: well-differentiated jejunal-ile-al tumor/carcinoma. Neuroendocrinology 2008; 87:8-19.
31. Hellman P, Lundström T, Ohrvall U, Eriksson B, Skogseid B, Oberg K, Tiensuu Janson E, Akerström G: Effect of surgery on the outcome of midgut carcinoid disease with lymph node and liver metastases. World J Surg 2002; 26: 991-997.
32. Givi B, Pommier SJ, Thomson AK, Diggs BS, Pommier RD: Operative resection of primary carcinoid neoplasms in patients with liver metastases yields significantly better survival. Surgery 2006; 140: 891-898.